← All trials
NCT02509494
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2015
- Primary completion
- Sep 30, 2018
- Completion date
- May 12, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 1019
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Johnson and JohnsonLead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of LondonCollaborator
- Grameen FoundationCollaborator
- World Vision of IrelandCollaborator
- Government of Sierra LeoneCollaborator
- University of OxfordCollaborator
- Janssen Pharmaceutica NVStudy director
- University of Sierra LeoneCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.